Monitoring phenylalanine (Phe) levels in the blood of individuals with phenylketonuria (PKU) is a critical component of therapy. Existing tests for PKU require high-resource laboratories, which are not available to many populations and cannot provide the real-time feedback required for effective therapy monitoring. It would be ideal to develop an...
Laboratory-based testing does not allow for the sufficiently rapid return of data to enable optimal therapeutic monitoring of patients with metabolic diseases such as phenylketonuria (PKU). The typical turn-around time of several days for current laboratory-based testing is too slow to be practically useful for effective monitoring or optimizing therapy....